In the GAIN study, decreasing the secukinumab dosing interval showed a trend towards higher skin clearance rates in initial suboptimal responders (≥ PASI75 to < PASI90), potentially resulting from proportionally increased secukinumab serum concentrations. 42 Regarding real‐life clinical cases, off‐label secukinumab dose intensification has already led to clinically significant improvements without reporting any new or unexpected safety findings.
← all excerpts
Therapeutic drug monitoring in dermatology: the way towards dose optimization of secukinumab in chronic plaque psoriasis.
1
—
—